Ascendis Pharma ADR (ASND)

Jan 12, 2025, 5:00 PM EST - 5 days ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:30 AM EST - 11 days ago

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 8:30 AM EST - 4 weeks ago

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

Dec 16, 2024, 8:30 AM EST - 4 weeks ago

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

Dec 12, 2024, 4:01 PM EST - 5 weeks ago

FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Dec 10, 2024, 7:00 AM EST - 5 weeks ago

Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets

Nov 14, 2024, 10:53 PM EST - 2 months ago

Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:01 PM EST - 2 months ago

Ascendis Pharma Reports Third Quarter 2024 Financial Results

Sep 30, 2024, 8:30 AM EDT - 3 months ago

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Sep 30, 2024, 8:30 AM EDT - 3 months ago

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

Sep 19, 2024, 8:16 PM EDT - 4 months ago

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Sep 18, 2024, 4:04 PM EDT - 4 months ago

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Sep 16, 2024, 12:18 PM EDT - 4 months ago

Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year

Sep 16, 2024, 7:00 AM EDT - 4 months ago

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Sep 13, 2024, 8:30 AM EDT - 4 months ago

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

Sep 11, 2024, 5:37 PM EDT - 4 months ago

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

Sep 5, 2024, 1:30 AM EDT - 4 months ago

Ascendis Pharma Takes A Big Price Cut On Skytrofa

Sep 4, 2024, 5:02 PM EDT - 4 months ago

Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In

Sep 4, 2024, 9:09 AM EDT - 4 months ago

Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut

Sep 3, 2024, 9:41 PM EDT - 4 months ago

Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript

Sep 3, 2024, 5:06 PM EDT - 4 months ago

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Sep 3, 2024, 5:04 PM EDT - 4 months ago

Ascendis Pharma Reports Second Quarter 2024 Financial Results

Aug 28, 2024, 8:30 AM EDT - 5 months ago

Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024

Aug 13, 2024, 5:25 AM EDT - 5 months ago

Ascendis Pharma: Yorvipath Approved, Launch Delayed, Many Other Updates Coming Up

Aug 12, 2024, 8:51 AM EDT - 5 months ago

Ascendis Pharma's stock surges after FDA approval for first and only treatment for rare disease

Aug 12, 2024, 7:23 AM EDT - 5 months ago

FDA approves Ascendis Pharma's hormone disorder therapy

Jul 29, 2024, 5:52 AM EDT - 6 months ago

Weaker USD, Revenue Growth, And TransCon Technology Make Ascendis Pharma A Strong Buy Opportunity

Jun 24, 2024, 4:45 PM EDT - 7 months ago

Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024

Jun 4, 2024, 4:01 PM EDT - 8 months ago

Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 4:01 PM EDT - 8 months ago

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

May 30, 2024, 8:30 AM EDT - 8 months ago

Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024

May 14, 2024, 2:43 PM EDT - 8 months ago

FDA extends review of Ascendis Pharma's hormone disorder therapy

May 14, 2024, 2:31 PM EDT - 8 months ago

Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism

May 13, 2024, 8:30 AM EDT - 8 months ago

Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial

May 9, 2024, 8:30 AM EDT - 9 months ago

Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024

May 8, 2024, 6:55 AM EDT - 9 months ago

An Update On Ascendis Pharma's Path To Profitability

May 4, 2024, 12:33 PM EDT - 9 months ago

Ascendis Pharma A/S (ASND) Q1 2024 Earnings Call Transcript

May 2, 2024, 4:01 PM EDT - 9 months ago

Ascendis Pharma Reports First Quarter 2024 Financial Results

Apr 25, 2024, 4:46 PM EDT - 9 months ago

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

Apr 24, 2024, 8:30 AM EDT - 9 months ago

United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Apr 10, 2024, 9:27 AM EDT - 10 months ago

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

AMGN CYTK DXCM EW HRTS IBB IHE

Mar 4, 2024, 8:30 AM EST - 11 months ago

Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

Feb 7, 2024, 10:18 PM EST - 1 year ago

Ascendis Pharma A/S (ASND) Q4 2023 Earnings Call Transcript

Feb 7, 2024, 4:01 PM EST - 1 year ago

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

Feb 7, 2024, 8:30 AM EST - 1 year ago

Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 31, 2024, 4:15 PM EST - 1 year ago

Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024

Jan 31, 2024, 4:01 PM EST - 1 year ago

Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

Jan 29, 2024, 8:30 AM EST - 1 year ago

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

Jan 11, 2024, 8:33 AM EST - 1 year ago

Ascendis Pharma's Ambitious Vision 2030

Jan 7, 2024, 5:45 PM EST - 1 year ago

Ascendis Pharma Introduces Vision 2030